Highlights of Shire – Baxalta Deal
Posted on18 Jan 2016
Comments0
Shire acquires drug maker Baxalta on recently announced deal valued at about $32 billion. The combination would create a giant in the treatment... Read More
Health Canada approves Baxalta’s Obizur to treat bleeding episodes in patients with acquired haemophilia A
Baxalta Incorporated, a global biopharmaceutical leader, announced that Health Canada has approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of... Read More